Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Domvanalimab + zimberelimab + chemotherapy vs nivolumab + chemotherapy in untreated advanced upper gastrointestinal adenocarcinoma
CTR20233470Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of domvanalimab, zimberelimab, nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Gilead Sciences. Started Nov 2023; status: terminated.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20233470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233470.